Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095153 Target Snapshot

Phosphodiesterase; PDE3 & PDE4 · SELECTIVITY GROUP · Homo sapiens

201Compounds
26Assays
2Approved Drugs
35.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P27815. Use UniProt P27815 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P27815 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Phosphodiesterase; PDE3 & PDE4 as ChEMBL target CHEMBL2095153, mapped to UniProt P27815. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Phosphodiesterase; PDE3 & PDE4
SELECTIVITY GROUP · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2095153
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P27815
3',5'-cyclic-AMP phosphodiesterase 4A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Phosphodiesterase; PDE3 & PDE4 is the right protein anchor across sources, using UniProt P27815 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label3',5'-cyclic-AMP phosphodiesterase 4A
UniProt AccessionP27815
Component TypeProtein
Sequence Length886 aa

3',5'-cyclic-AMP phosphodiesterase 4A

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Phosphodiesterase; PDE3 & PDE4, mapped to UniProt P27815. ChEMBL maps the protein component as 3',5'-cyclic-AMP phosphodiesterase 4A. Sequence length is 886 aa.

Mapped IDP27815
Review namePhosphodiesterase; PDE3 & PDE4
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

2
Approved
2
Phase III
4
Phase II
Assay Mix

Activity Type Distribution

IC5034.0
KI1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL38017 7.89 IC50 13.0 Preclinical
CHEMBL46127 7.44 IC50 36.0 Preclinical
CHEMBL2114400 7.14 IC50 73.0 Preclinical
CHEMBL38224 7.1 Ki 80.0 Clinical
CHEMBL280360 6.92 IC50 120.0 Preclinical
CHEMBL440593 6.92 IC50 120.0 Preclinical
CHEMBL38224 6.89 IC50 130.0 Clinical
CHEMBL19984 6.8 IC50 160.0 Preclinical
CHEMBL416178 6.8 IC50 160.0 Preclinical
CHEMBL417529 6.77 IC50 170.0 Preclinical
Distribution

pChEMBL Value Distribution

5
5.0
6
5.5
7
6.0
8
6.5
3
7.0
1
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

26
Total Assays
34
Tested Compounds
1
Assay Types
Binding — 26 assays, 34 compounds
BAO Format Assays Compounds Avg pChEMBL
protein format 20 24 5.9
assay format 3 0
tissue-based format 2 10 6.5
organism-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine